CSL Limited (OTCMKTS:CSLLY - Get Free Report) saw a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 4,700 shares, a growth of 683.3% from the November 30th total of 600 shares. Based on an average trading volume of 102,500 shares, the short-interest ratio is currently 0.0 days.
Shares of CSLLY stock traded down $0.19 during mid-day trading on Thursday, hitting $88.56. 86,311 shares of the company's stock were exchanged, compared to its average volume of 37,930. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.18 and a quick ratio of 0.97. CSL has a fifty-two week low of $83.31 and a fifty-two week high of $109.00. The stock has a 50-day simple moving average of $92.02 and a two-hundred day simple moving average of $97.54.
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CSL, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CSL wasn't on the list.
While CSL currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.